HK1061357A1 - Fibrate-statin combinations with reduced fed-fasted effects - Google Patents
Fibrate-statin combinations with reduced fed-fasted effectsInfo
- Publication number
- HK1061357A1 HK1061357A1 HK04102918A HK04102918A HK1061357A1 HK 1061357 A1 HK1061357 A1 HK 1061357A1 HK 04102918 A HK04102918 A HK 04102918A HK 04102918 A HK04102918 A HK 04102918A HK 1061357 A1 HK1061357 A1 HK 1061357A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fenofibrate
- statin
- fibrate
- fed
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Meat, Egg Or Seafood Products (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27015701P | 2001-02-22 | 2001-02-22 | |
PCT/US2001/012747 WO2002067901A1 (en) | 2001-02-22 | 2001-04-20 | Fibrate-statin combinations with reduced fed-fasted effects |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1061357A1 true HK1061357A1 (en) | 2004-09-17 |
Family
ID=23030144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04102918A HK1061357A1 (en) | 2001-02-22 | 2004-04-26 | Fibrate-statin combinations with reduced fed-fasted effects |
Country Status (14)
Country | Link |
---|---|
US (3) | US6534088B2 (xx) |
EP (1) | EP1361867B1 (xx) |
JP (1) | JP2004523552A (xx) |
CN (1) | CN1273112C (xx) |
AT (1) | ATE357216T1 (xx) |
AU (1) | AU2001259099B2 (xx) |
CA (1) | CA2440355C (xx) |
DE (1) | DE60127457T2 (xx) |
ES (1) | ES2284646T3 (xx) |
HK (1) | HK1061357A1 (xx) |
NZ (1) | NZ527408A (xx) |
PL (1) | PL202778B1 (xx) |
TW (1) | TWI288000B (xx) |
WO (1) | WO2002067901A1 (xx) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US7459283B2 (en) | 2002-02-04 | 2008-12-02 | Elan Pharma International Limited | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
NZ511792A (en) | 1998-11-20 | 2003-08-29 | Skyepharma Canada Inc | Dispersible phospholipid stabilized microparticles |
HUP0200258A2 (hu) | 1999-03-05 | 2002-05-29 | The Procter & Gamble Co. | C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US8586094B2 (en) | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
WO2003013607A1 (en) * | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR |
AU2002353659A1 (en) * | 2001-12-18 | 2003-07-15 | Synthon B.V. | Simvastatin dosage forms |
AU2003225752A1 (en) * | 2002-03-12 | 2003-09-29 | Paul S. Phillips | Method of diagnosing statin myopathy |
WO2003103640A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
AU2003241478A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
DE10248619A1 (de) * | 2002-10-18 | 2004-04-29 | Bayer Ag | Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden |
FR2851734B1 (fr) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede |
GEP20084406B (en) * | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
EP1651194B1 (en) * | 2003-08-06 | 2010-03-31 | Galephar M/F | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
MXPA06003813A (es) * | 2003-10-10 | 2006-06-14 | Lifecycle Pharma As | Forma solida de dosificacion que comprende un fibrato y una estatina. |
US7658944B2 (en) * | 2003-10-10 | 2010-02-09 | Lifecycle Pharma A/S | Solid dosage form comprising a fibrate |
US20070014846A1 (en) * | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
US20050096390A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
JP4771956B2 (ja) | 2003-11-04 | 2011-09-14 | スパーナス ファーマシューティカルズ インコーポレイテッド | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 |
DK2210605T3 (en) | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
EP1680099B1 (en) * | 2003-11-07 | 2009-04-15 | JJ Pharma, Inc. | Hdl-boosting combination therapy complexes |
WO2005053683A1 (en) | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
US20050170063A1 (en) * | 2004-01-29 | 2005-08-04 | Lalit Chordia | Production of powder and viscous material |
EP1563837A1 (en) * | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
WO2006011495A1 (ja) * | 2004-07-30 | 2006-02-02 | Kowa Company, Ltd. | 高コレステロール血症及び/又は高トリグリセリド血症治療剤 |
US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
EP1786414A4 (en) * | 2004-08-06 | 2008-04-09 | Transform Pharmaceuticals Inc | NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES |
CA2573316A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
WO2006037345A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical composition comprising fenofibrate and simvastatin |
KR20070104447A (ko) * | 2005-02-10 | 2007-10-25 | 라이프사이클 파마 에이/에스 | 페노피브레이트 및 HMG-CoA 리덕타제 억제제의 고정용량 배합물을 포함하는 안정한 약학 조성물 |
AU2006228525A1 (en) * | 2005-03-28 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
WO2006084475A2 (en) * | 2005-04-13 | 2006-08-17 | Lifecycle Pharma A/S | A tablet comprising a fibrate |
BRPI0616695A2 (pt) * | 2005-09-28 | 2011-06-28 | Dnp Canada Inc | combinação de poliquitosamina e fibrato para a prevenção e o tratamento de hiperlipidemia |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
EP1785133A1 (en) | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy |
AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
CN101494980A (zh) * | 2006-07-14 | 2009-07-29 | 兰贝克赛实验室有限公司 | HMG-CoA还原酶抑制剂的多晶型形式及其应用 |
BRPI0621942A2 (pt) | 2006-08-04 | 2011-10-18 | Aska Pharm Co Ltd | preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação |
US7915247B1 (en) | 2006-08-21 | 2011-03-29 | Mutual Pharmaceutical Company, Inc. | Methods of use of fenofibric acid |
MXPA06010973A (es) * | 2006-09-25 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia. |
US7731604B2 (en) * | 2006-10-31 | 2010-06-08 | Taylor Made Golf Company, Inc. | Golf club iron head |
WO2008057048A1 (en) * | 2006-11-09 | 2008-05-15 | Nanomaterials Technology Pte Ltd | Nano & micro-sized particles of statin compounds and process for forming same |
WO2008095195A2 (en) * | 2007-02-02 | 2008-08-07 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of salinosporamide a |
WO2009016358A2 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
CN102307576A (zh) | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
EP2473044B1 (en) * | 2009-09-01 | 2014-04-02 | First Tech International Limited | Tocotrienol compositions |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
ES2960344T3 (es) | 2015-03-10 | 2024-03-04 | Shionogi Inc | Dispersiones sólidas que comprenden ospemifeno |
US20170312359A1 (en) * | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2803582A (en) * | 1956-07-16 | 1957-08-20 | Leonid S Cherney | Local anesthetic composition |
NL120093C (xx) * | 1958-07-24 | |||
US3137631A (en) * | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
US3216897A (en) * | 1961-11-02 | 1965-11-09 | Air Reduction | Injectable anesthetic |
US3594476A (en) * | 1969-05-12 | 1971-07-20 | Massachusetts Inst Technology | Submicron aqueous aerosols containing lecithin |
US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
NL7012832A (xx) * | 1970-08-29 | 1972-03-02 | ||
US3715432A (en) * | 1971-01-22 | 1973-02-06 | Massachusetts Inst Technology | Submicron aqueous aerosols containing lecithin |
US3794476A (en) * | 1972-12-26 | 1974-02-26 | Ppg Industries Inc | Method for thermally tempering glass sheet by liquid quenching |
GB1413186A (en) * | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
GB1472793A (en) * | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
US4798846A (en) * | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
US3965255A (en) * | 1974-05-01 | 1976-06-22 | E. E. Eljim Ecology Ltd. | Controlled drug releasing preparations |
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
CH588887A5 (xx) * | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
US4073943A (en) * | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
JPS5186117A (en) * | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
JPS5231981A (en) * | 1975-08-18 | 1977-03-10 | Takeda Chem Ind Ltd | Microcapsule preparation method |
CA1077842A (en) * | 1975-10-09 | 1980-05-20 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
GB1578776A (en) * | 1976-06-10 | 1980-11-12 | Univ Illinois | Hemoglobin liposome and method of making the same |
US4078052A (en) * | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
US4086257A (en) * | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
US4320121A (en) * | 1976-10-12 | 1982-03-16 | Sears Barry D | Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds |
US4351831A (en) * | 1977-11-02 | 1982-09-28 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering isoxsurpine and choline |
US4356167A (en) * | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4529561A (en) * | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
GB2026340B (en) * | 1978-07-03 | 1982-12-22 | Ash P | Stabilising microvesicles |
US4329332A (en) * | 1978-07-19 | 1982-05-11 | Patrick Couvreur | Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them |
US4219548A (en) * | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
DE2856333C2 (de) * | 1978-12-27 | 1983-09-22 | A. Nattermann & Cie GmbH, 5000 Köln | Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung |
US4369182A (en) * | 1978-09-27 | 1983-01-18 | A. Nattermann & Cie Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
GR73668B (xx) * | 1978-11-21 | 1984-03-28 | Hoffmann La Roche | |
US4328222A (en) * | 1978-11-21 | 1982-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions for parenteral or local administration |
US4378354A (en) * | 1978-12-27 | 1983-03-29 | A. Nattermann & Cie. Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
US4316884A (en) * | 1979-01-25 | 1982-02-23 | Adria Laboratories, Inc. | Sustained release pharmaceutical formulation |
DE2914788A1 (de) * | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
JPS6030652B2 (ja) * | 1979-05-07 | 1985-07-17 | 株式会社ミドリ十字 | 静脈注射用脂肪乳剤 |
JPS562353A (en) * | 1979-06-20 | 1981-01-12 | Ricoh Co Ltd | Novel disazo compound and its preparation |
CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
DE3003886A1 (de) * | 1980-02-02 | 1981-08-13 | Olympia Werke Ag, 2940 Wilhelmshaven | Farbbandkassette fuer eine schreib- o.ae. bueromaschine |
AR220263A1 (es) * | 1980-02-19 | 1980-10-15 | Bago Lab Sa | Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad |
JPS609726B2 (ja) * | 1980-05-15 | 1985-03-12 | 株式会社 ミドリ十字 | ステロイド製剤 |
US4331654A (en) * | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
US4394372A (en) * | 1980-12-22 | 1983-07-19 | The Procter & Gamble Company | Process for making lipid membrane structures |
US4397846A (en) * | 1981-05-15 | 1983-08-09 | Murray Weiner | Storage-stable lipid vesicles and method of preparation |
US5030453A (en) * | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
JPS601122A (ja) * | 1983-06-20 | 1985-01-07 | Green Cross Corp:The | ビフエニリルプロピオン酸誘導体脂肪乳剤 |
US4492720A (en) * | 1983-11-15 | 1985-01-08 | Benjamin Mosier | Method of preparing microspheres for intravascular delivery |
US4532089A (en) * | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
JPS6176414A (ja) * | 1984-09-21 | 1986-04-18 | Shionogi & Co Ltd | リポソーム製剤の製法 |
JPS61174940A (ja) * | 1985-01-29 | 1986-08-06 | Oogawara Kakoki Kk | ワックス類コーテイング単核状マイクロカプセルおよびその製造方法 |
JPH0688911B2 (ja) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | インフルエンザワクチン及びその製造方法 |
US4766046A (en) * | 1985-09-27 | 1988-08-23 | Liposome Technology, Inc. | Stabilized liposome/amphotericin composition and method |
JPH0617309B2 (ja) * | 1985-11-29 | 1994-03-09 | 株式会社ビタミン研究所 | アドリアマイシン包埋リポソ−ム製剤 |
US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
US4806352A (en) * | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
DE3623376A1 (de) * | 1986-07-11 | 1988-01-21 | Behringwerke Ag | Pharmazeutische formulierung und verfahren zu deren herstellung |
FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
US4776991A (en) * | 1986-08-29 | 1988-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Scaled-up production of liposome-encapsulated hemoglobin |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4839111A (en) * | 1987-02-02 | 1989-06-13 | The University Of Tennessee Research Corporation | Preparation of solid core liposomes |
US5154930A (en) * | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US5744477A (en) * | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
JP2785981B2 (ja) * | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | 乳化組成物 |
US5246707A (en) * | 1990-04-26 | 1993-09-21 | Haynes Duncan H | Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes |
US5091187A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5785976A (en) * | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
US5637625A (en) * | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
ES2252780T3 (es) * | 1996-08-22 | 2006-05-16 | Jagotec Ag | Composiciones que comprenden microparticulas de sustancias insolubles en agua y metodo para su preparacion. |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
NZ511792A (en) | 1998-11-20 | 2003-08-29 | Skyepharma Canada Inc | Dispersible phospholipid stabilized microparticles |
DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AU5711501A (en) * | 2000-04-20 | 2001-11-07 | Rtp Pharma Inc | Improved water-insoluble drug particle process |
EP1280604B1 (en) * | 2000-05-10 | 2008-03-19 | Jagotec AG | Media milling |
US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
-
2001
- 2001-04-20 AT AT01932584T patent/ATE357216T1/de not_active IP Right Cessation
- 2001-04-20 EP EP01932584A patent/EP1361867B1/en not_active Expired - Lifetime
- 2001-04-20 NZ NZ527408A patent/NZ527408A/xx not_active IP Right Cessation
- 2001-04-20 PL PL364174A patent/PL202778B1/pl unknown
- 2001-04-20 US US09/838,583 patent/US6534088B2/en not_active Expired - Lifetime
- 2001-04-20 TW TW090109551A patent/TWI288000B/zh not_active IP Right Cessation
- 2001-04-20 CN CNB018231640A patent/CN1273112C/zh not_active Expired - Fee Related
- 2001-04-20 AU AU2001259099A patent/AU2001259099B2/en not_active Ceased
- 2001-04-20 DE DE60127457T patent/DE60127457T2/de not_active Expired - Lifetime
- 2001-04-20 WO PCT/US2001/012747 patent/WO2002067901A1/en active IP Right Grant
- 2001-04-20 JP JP2002567269A patent/JP2004523552A/ja active Pending
- 2001-04-20 ES ES01932584T patent/ES2284646T3/es not_active Expired - Lifetime
- 2001-04-20 CA CA2440355A patent/CA2440355C/en not_active Expired - Fee Related
-
2003
- 2003-03-17 US US10/388,597 patent/US20040086571A1/en not_active Abandoned
-
2004
- 2004-04-26 HK HK04102918A patent/HK1061357A1/xx not_active IP Right Cessation
-
2011
- 2011-11-14 US US13/295,708 patent/US20120064160A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TWI288000B (en) | 2007-10-11 |
DE60127457D1 (de) | 2007-05-03 |
CA2440355A1 (en) | 2002-09-06 |
EP1361867B1 (en) | 2007-03-21 |
WO2002067901A1 (en) | 2002-09-06 |
CA2440355C (en) | 2011-03-08 |
PL364174A1 (en) | 2004-12-13 |
ATE357216T1 (de) | 2007-04-15 |
PL202778B1 (pl) | 2009-07-31 |
CN1505502A (zh) | 2004-06-16 |
NZ527408A (en) | 2005-04-29 |
US6534088B2 (en) | 2003-03-18 |
ES2284646T3 (es) | 2007-11-16 |
AU2001259099B2 (en) | 2005-12-22 |
US20040086571A1 (en) | 2004-05-06 |
DE60127457T2 (de) | 2007-11-29 |
CN1273112C (zh) | 2006-09-06 |
US20120064160A1 (en) | 2012-03-15 |
US20020161032A1 (en) | 2002-10-31 |
EP1361867A1 (en) | 2003-11-19 |
JP2004523552A (ja) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1061357A1 (en) | Fibrate-statin combinations with reduced fed-fasted effects | |
ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
IL112518A0 (en) | Thyroid hormone fast dispersing pharmaceutical composition | |
AP1637A (en) | Celecoxib compositions. | |
RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
YU66600A (sh) | Farmaceutski preparati koji mogu da budu gelirani | |
MY138227A (en) | Valdecoxib compositions | |
TW200718418A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
HUP0301518A2 (hu) | Légzési rendellenességek kezelésére alkalmas száraz porkészítmény és eljárás az előállítására | |
KR970705553A (ko) | 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents) | |
UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
IT1187687B (it) | Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi | |
DE60016007D1 (de) | Ernährungszusammensetzung, die einen vorläufer von anandamide enthält | |
BG106155A (en) | Novel derivatives and analogues of galanthamin | |
BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
WO2001081328A3 (en) | Thiazolidinedione analogues and their use for the treatment of diabetes | |
ATE183648T1 (de) | Arzneimittel enthaltend mischungen von höheren primären aliphatischen alkoholen zur behandlung von hypercholesterolämie und hyperlipoproteinämie typ ii und zur stimulation des sexuellen verhaltens bei tieren und menschen | |
UA74388C2 (uk) | Фармацевтичні композиції тизоксаніду і нітазоксаніду | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
PL371264A1 (en) | Method for the treatment of bone disorders | |
JP2003523920A5 (xx) | ||
BR9917605A (pt) | Composição substituta de plasma | |
MXPA03007017A (es) | Medicamentos. | |
EP1263435A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF LIVER CIRRHOSIS AND CIRRHOSIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160420 |